GlassScriptPhysician profile
Taline Khoukaz
NPI 1639368103
$4,031.48
in general payments reported to CMS, 2019-2025
30 companies · $1,262 in 2025
The $1,262 reported for 2025 was more than what 90% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $138 · 2022: $563 · 2023: $917 · 2024: $1,151 · 2025: $1,262.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,644 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $480 · Education: $205.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,644.49 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $480.00 |
| Education | $205.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Taiho Oncology, INC. | $683.44 | 2022-2025 | |
| Astellas Pharma US INC | $430.99 | 2023-2025 | Vyloy, Padcev |
| Astrazeneca Pharmaceuticals LP | $305.88 | 2024-2025 | Calquence |
| Sobi, INC | $295.22 | 2022-2025 | |
| Incyte Corporation | $204.15 | 2023-2025 | Zynyz, Pemazyre, Monjuvi |
| Genzyme Corporation | $167.12 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $163.59 | 2021-2023 | |
| Gilead Sciences, INC. | $152.78 | 2024-2025 | Trodelvy |
| E.R. Squibb & Sons, L.L.C. | $150.64 | 2024-2025 | Opdivo, Opdualag |
| Novartis Pharmaceuticals Corporation | $146.89 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $143.86 | 2022-2024 | Keytruda |
| Amgen INC. | $141.85 | 2021-2023 | Vectibix, Xgeva, Nplate |
| Takeda Pharmaceuticals U.S.A., INC. | $140.17 | 2024-2025 | Fruzaqla, Ninlaro |
| Beone Medicines USA, INC. | $117.14 | 2025 | Brukinsa |
| Alexion Pharmaceuticals, INC. | $110.80 | 2023-2024 | Ultomiris |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $105.12 | 2021-2024 | |
| Syndax Pharmaceuticals, INC. | $102.91 | 2025 | |
| Daiichi Sankyo INC. | $70.20 | 2021-2025 | Datroway |
| Abbvie INC. | $64.47 | 2024-2025 | |
| Tersera Therapeutics LLC | $47.25 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $45.95 | 2022 | |
| Caris Mpi, INC. | $40.89 | 2025 | Mi Cancer Seek |
| Jazz Pharmaceuticals INC. | $32.13 | 2024 | |
| Deciphera Pharmaceuticals INC. | $30.82 | 2023 | Qinlock |
| Alnylam Pharmaceuticals INC. | $29.69 | 2022 | |
| Lilly USA, LLC | $28.09 | 2024 | Jaypirca, Verzenio |
| Springworks Therapeutics, INC. | $24.41 | 2024 | Ogsiveo |
| Rigel Pharmaceuticals, INC. | $22.89 | 2024 | Rezlidhia, Tavalisse |
| Dova Pharmaceuticals | $16.45 | 2021 | |
| Pfizer INC. | $15.69 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taline Khoukaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.